I disagree D1475. Targetting similar rare diseases give Neuren greater leverage with the FDA when it comes to expediting approval timeframes together with the added bonus of picking up a few PRVs along the way. From my very limited scientific understanding, Parkinson's is an atrophy of the brain whereas retts, angelman, PH, PWS are all very similar in their neurological actions and symptoms.
Ann: Investor Presentation, 14 March 2023, page-85
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |